Blue Matter

#Psychedelic medicines are moving from clinical promise toward more real-world use, & the questions facing companies are shifting accordingly. Positive late-stage data, a more supportive regulatory climate, & a wave of Big Pharma investment have changed the conversation from whether these therapies work to what it will take for them to succeed. In this white paper, Blue Matter’s Jordan Burgess examines 5 issues that will shape the field & that biopharma companies must address >> https://lnkd.in/eWjJ55qg #biotech #pharmaceuticals #psychedelics #psychedelicmedicines #PTSD #TRD #CNS #CentralNervousSystem

Tomorrow at Intellus Worldwide Institute 2026, Andrew Pilecki and David Spears will take the stage to explore an increasingly important question: What drives patients to adopt, or avoid, a new telehealth offering? In their session, “Decoding Telehealth Adoption in a Primary Care Condition: A Behavioral Science Approach,” Andrew and David will discuss how the COM-B framework can help uncover the capability, opportunity, and motivation factors influencing patient behavior, and how those insights can be translated into actionable launch strategies. 🌟 October 1 | 11:15 AM @ The Hyatt Regency D-F Attending Intellus Worldwide Institute? We hope you’ll join Andrew and David tomorrow! #IntellusWW #Telehealth #BehavioralScience #MarketResearch #LifeSciences #Biopharma

Traditional #MarketResearch does a good job of capturing what stakeholders say but often misses the unconscious drivers, biases, emotions, & contexts that shape behavior >> Learn how Blue Matter's #BehavioralScience Center of Excellence helps clients bridge the gap between what respondents say & what they actually do >> https://lnkd.in/eENhGK89 #biotech #pharmaceutical #primaryresearch

Tara Austraat-Churik will be joining industry leaders at BioFuture 2026 by Demy-Colton in New York City for a “Big Think” Plenary Session focused on AI and deep tech in health innovation. On October 28, Tara will participate in AI & Deep Tech: Refining Health Innovation – Drug Discovery, Diagnostics and Delivery, exploring the evolving role of AI and deep tech in drug discovery and the opportunities that remain to improve clinical success and ultimately deliver greater impact for patients. October 28 | 2:00–2:55 PM in New York City Attending BioFuture? Join Tara and her fellow panelists for the discussion. Learn more about Tara’s session and our participation at BioFuture > https://lnkd.in/gNaDh8xK #BioFuture2026 #ArtificialIntelligence #DeepTech #DrugDiscovery #Biopharma #LifeSciences

Antonio Iervolino will be speaking at the 35th European Pharma and Biotech Project, Program and Portfolio Management Conference by Why Summits in London on October 21. During his session, “Right Bet, Right Money, Right Time: What 400 Launches Reveal About the Quality of Our Portfolio Decisions,” Antonio will draw on Blue Matter’s benchmarking of 400 launches, alongside new research with senior pharma and biotech launch leaders, to examine how strategic portfolio choices hold up against real-world outcomes. The session will explore where value is won and lost in the years surrounding launch and how leaders can make more informed decisions about which assets to back, how much to invest, and when to commit. Learn more about Antonio’s session: https://lnkd.in/eVh-T8NC #PortfolioStrategy #Pharma #Biotech #ProductLaunch #PPM

European Academy of Dermatology and Venereology (EADV) Congress 2026 is just a few days away! Nikos Kontos and Jenna Riffell will be in Vienna this week for one of the leading events bringing together the global dermatology and venereology community. They’re looking forward to hearing the latest perspectives from across the field, catching up with colleagues, and connecting with others working across dermatology and biopharma. Will you be at EADV Congress 2026? Be sure to say hello to Nikos and Jenna while you’re there! #EADV2026 #EADVCongress #Dermatology #Biopharma #LifeSciences

Blue Matter is heading to New York City for the 16th Annual Association for Value-Based Cancer Care (AVBCC) Summit, taking place October 7–9. Partners Mary Roberts, Milena Sullivan, and Tara Austraat-Churik will each take part in discussions on October 7, contributing their perspectives across several important topics shaping oncology and the broader biopharma landscape, including patient access and affordability, evolving payer dynamics, and the changing global clinical research environment. If you’ll be at AVBCC, we hope you’ll join Mary, Milena, and Tara for their respective sessions and connect with the Blue Matter team while you’re there. Swipe through for more information on each session. Learn more about where to find Blue Matter at AVBCC 2026 > https://lnkd.in/exRchU5V #AVBCC26 #Oncology #ValueBasedCare #ClinicalResearch #Biopharma

When cell / gene therapy launches don't meet expectations, what's the culprit? In this comprehensive eBook, Tim Barder, PhD, Emily Joel Mercer, PhD, and guest author, Joe DePinto provide the answers to that question. They lay out 10 success factors for launching & commercializing cell / gene therapies & explore each one in detail >> https://lnkd.in/ebmxCiV7 #celltherapies #genetherapies #celltherapy #genetherapy #biotech #pharmaceutical

Yesterday at LSX Congress USA in Boston, Pankaj Oza moderated two panel discussions bringing together industry leaders to explore key considerations shaping biopharma growth and commercialization. The first discussion, “Breaking into New Markets: Strategies for Global Biopharma Expansion,” explored the opportunities and challenges companies face as they evaluate new markets and build strategies for international growth. Later in the day, Pankaj moderated “Commercializing Rare Disease Therapies: Challenges & Opportunities,” with the panel sharing perspectives on the unique complexities of bringing rare disease therapies to patients and successfully navigating commercialization. We were also glad to have several members of our team at LSX Congress USA, joining the conversations and connecting with leaders from across the biopharma community throughout the event. Thank you to all of the panelists who joined Pankaj and shared their experiences and perspectives. We’ll be sharing additional insights from the discussions and exploring some of these themes in greater depth in the coming days. Pankaj Oza, Ayushman Ghosh, Naina Shehzeen A., Emily Borrello #LSXUSA #Biopharma #Biotechnology #LifeSciences #RareDisease #Commercialization

Andrew Pilecki and David Spears will be speaking at Intellus Worldwide Institute 2026 next week, exploring how behavioral science can help uncover the factors shaping patient adoption of telehealth. During their session, “Decoding Telehealth Adoption in a Primary Care Condition: A Behavioral Science Approach,” Andrew and David will share how the COM-B framework, focused on capability, opportunity, and motivation, can identify what drives or prevents patients from accessing an existing treatment through a new telehealth offering, and how those insights can inform actionable launch strategies. 🌟 October 1 | 11:15 AM @ The Hyatt Regency D-F If you’ll be attending Intellus Worldwide Institute, we hope you’ll join them for the discussion! #IntellusWW #Telehealth #BehavioralScience #MarketResearch #LifeSciences #Biopharma